Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
The peptide occupies an innate repair receptor. It does not assemble the erythropoietin molecule and it is not mapped here as a red-cell growth factor. Cytokine and NF-kB directions are experimental class signals, not a seeded anti-inflammatory trial.
Calling it EPO does not make it erythropoietin. Forums that treat it as a blood-builder are describing a different protein.
Erythropoietin has a helix that, as this short peptide, is discussed at the innate repair receptor rather than at red-cell production.
Experimental work connects that receptor to lower inflammatory signaling. This sheet stores that as a speculative cytokine and NF-kB direction. It does not store a hemoglobin effect.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
EPO fragment talk · unverified
Forums call ARA-290 an EPO fragment and sometimes talk about it as if it were erythropoietin. The peptide is eleven residues from one helix. This sheet does not map it onto red-cell production.
Theme summarized from public discussion. Not a quoted post, not a trial, and not a dose.